Скачать или смотреть Targeting GSK-3ß with elraglusib in pancreatic cancer

Devalingam Mahalingam, MD, PhD, Northwestern University, Evanston, IL, discusses the rationale for targeting GSK-3ß with elraglusib in pancreatic cancer. Because GSK-3ß plays a multi-regulatory role, targeting through elraglusib affects key tumor pathways like epithelial-mesenchymal transition, fibrosis, and immune response. Elraglusib has shown efficacy across multiple tumor types, including a complete response in melanoma, and may resensitize chemo-refractory patients when combined with gemcitabine and nab-paclitaxel. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.